Microbial & Pharmacological Assessment of Chlorhexidine

Status Completed

Clinical Trial Summary

Ventilator-associated pneumonia (VAP) is the most frequent life-threatening nosocomial infection in the ICU. Oropharyngeal colonization with bacterial pathogens is the first step toward lung infection. Oral hygiene with Chlorhexidine mouth wash (CMW) is among the most widespread preventive measure to prevent VAP. Precise microbial documentation of CMW efficacy on oropharyngeal colonization is lacking. Investigators wish to determine CMW antimicrobial efficacy in ICU ventilated patients and to measure chlorhexidine residual concentration in patients' saliva at the same time-points after CMW.

Clinical Trial Description

Ventilator associated pneumonia (VAP) is the most frequent life-threatening nosocomial infection in the ICU. Oropharyngeal colonization with bacterial pathogens is the first step toward lung infection. Oral hygiene with Chlorhexidine mouth wash (CMW) is among the most widespread preventive measure to prevent VAP. Although many guidelines and expert opinions recommend oral hygiene with chlorhexidine, optimal conditions of CMW use remain unknown. In addition, precise microbial documentation of CMW efficacy on oropharyngeal colonization is lacking. Investigators wish to determine CMW antimicrobial efficacy in ICU ventilated patients and to measure chlorhexidine residual concentration in the saliva at the same time-points after CMW.

In the participanting unit, CMW is performed every 6 hours with a 0.12% chlorhexidine solution.

Hence, microbial oropharyngeal sampling will be performed 6h after the last CMW (and just before the next one), to assess oropharyngeal colonization and then 15 minutes, 1 hour, 2 hours, 4 hours, and 6 hours after a new CMW to assess CMW efficacy in terms of bacterial growth.

In a subset of patients, 0.5 mL of saliva will be collected with a syringe at the same time points, with an additional T30 time (at 30 minutes) to measure chlorhexidine concentration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03290105
Study type	Observational
Source	Hôpital Louis Mourier
Contact
Status	Completed
Phase	N/A
Start date	January 27, 2014
Completion date	June 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05846399` - CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)	Phase 4
Recruiting	`NCT05904535` - Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
Not yet recruiting	`NCT04075344` - Effect of a Infection Control Program on the Reduction of Bacterial Contamination on NG Tube Feeding in RCHEs	N/A
Completed	`NCT05333133` - High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children	N/A
Recruiting	`NCT05950984` - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Recruiting	`NCT06283433` - A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT	N/A
Recruiting	`NCT06178822` - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Completed	`NCT03688321` - Probiotic on Prevention of GBS Vaginal Infection During Pregnancy	N/A
Completed	`NCT03244917` - Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias	N/A
Recruiting	`NCT04450680` - Beta-lactam Therapeutic Drug Monitoring in Singapore
Completed	`NCT05686577` - How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care
Recruiting	`NCT06093269` - Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)	Phase 4
Recruiting	`NCT05587283` - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women	Phase 1
Recruiting	`NCT03752424` - Topical Silver Nanoparticles for Microbial Activity	Phase 1
Completed	`NCT04440631` - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Active, not recruiting	`NCT05150015` - ElastoMeric Infusion Pumps for Hospital AntibioTICs	N/A
Completed	`NCT03816956` - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301	Phase 3
Terminated	`NCT03555981` - Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates	N/A
Completed	`NCT03133312` - Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery	Phase 4
Recruiting	`NCT04800575` - Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Microbial and Pharmacological Assessment of Chlorhexidine

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms